Inhibrx Biosciences, Inc. Common Stock INBX
$73.29
-23.38%
at last close
Market Cap$1.41 billion
P/E Ratio—
Div Yield—
Volume1.19M
52-Week Range
$28.16$155.29
Analyst Ratings
- Consensus
- Buy — 2 Buy · 0 Hold · 0 Sell (2 analysts)
- Avg. Price Target
- $197.50 (+169.5% upside)
Key Stats
- Today's Range
- $69.27 – $96.78
- 50-Day Range
- $69.27 – $131.01
- 52-Week Range
- $28.16 – $155.29
- Volume
- 1.19 million shs
- Average Volume
- 275K shs
- Market Cap
- $1.41 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 1.44%
- Days to Cover
- 1.00
About Inhibrx Biosciences, Inc. Common Stock
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Related Stocks
Compare head-to-head: INBX vs AMGN·INBX vs MRNA·INBX vs HALO·INBX vs RGEN
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.